Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia; Yuntao Zhang; Yanxia Wang; Hui Wang; Yunkai Yang; George F. Gao; Wenjie Tan; Guizhen Wu; Miao Xu; Zhiyong Lou; Weijin Huang; Wenbo Xu; Baoying Huang; Huijuan Wang; Wei Wang; Wei Zhang; Na Li; Zhiqiang Xie; Ling Ding; Wangyang You; Yuxiu Zhao; Xuqin Yang; Yang Liu; Qian Wang; Lili Huang; Yongli Yang; Guangxue Xu; Bojian Luo; Wen‐Ching Wang; Peipei Liu; Wanshen Guo; Xiaoming Yang

doi:10.1016/s1473-3099(20)30831-8

Keywords

MedicinePlaceboImmunogenicityTolerabilityClinical trialRandomized controlled trialInternal medicineAdverse effectImmunologyAntibody

Affiliated Institutions

Related Publications

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang , Gang Zeng , Hongxing Pan +17 more

With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Scie...

2020 The Lancet Infectious Diseases 1488 citations

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Hu-Dachuan Jiang , Ling Wang , Tao Jiang +18 more

A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID...

2020 The Lancet 1434 citations

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu Bennet , Jayanthi Wolf , Rodrigo Laureano +1 more

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...

2020 Toxicologic Pathology 47 citations

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti , Katie Ewer , Parvinder K. Aley +97 more

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a v...

2020 The Lancet 2590 citations

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov , Inna V. Dolzhikova , Dmitry V. Shcheblyakov +28 more

A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in pa...

2021 The Lancet 1799 citations

Publication Info

Year: 2020
Type: article
Volume: 21
Issue: 1
Pages: 39-51
Citations: 1200
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1200

OpenAlex

Cite This

APA Style

                            
                                
                                    Shengli Xia, 
                                
                                    Yuntao Zhang, 
                                
                                    Yanxia Wang
                                
                                et al.
                            
                            (2020). 
                            Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. 
                            The Lancet Infectious Diseases
                            , 21
                            (1)
                            , 39-51.
                            https://doi.org/10.1016/s1473-3099(20)30831-8
                        

Identifiers

DOI: 10.1016/s1473-3099(20)30831-8